Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Celgene
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
National Cancer Institute (NCI)
Celldex Therapeutics